Background
Materials and methods
Search strategy
Inclusion and exclusion criteria
Data extraction
Methodological quality assessment
miRNA-130b expression profile and prognosis
Statistical analysis
Results
Study identification
Study [Ref.] | Country | miRNA-130a | miRNA-130b | Histology | TNM stage | Sample | Assay | Follow-up (months) | Cut-off | HR (95% CI) | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OS | Other | OS | Other | OS | DFS/PFS | ||||||||
Jia 2019 [44] | China | 284 | Gastric cancer | I–IV | Frozen tissue | qRT-PCR | 50 | Median | 2.44 (1.35,4.40) | ||||
Peng 2018 [18] | China | 333 | DFS,333 | Gastric cancer | I–III | Serum | qRT-PCR | 59 | Median | 1.49 (0.99,2.26) | 1.38 (0.99,1.91) | ||
Liu 2018 [45] | China | 369 | Colorectal cancer | I–IV | Serum | qRT-PCR | 60 | Median | 2.36 (1.07,5.22) | ||||
Yang 2018 [46] | China | 60 | DFS,60 | Colorectal cancer | I–IV | Frozen tissue | qRT-PCR | 70 | Median | 2.25 (1.05,4.83) | |||
Asukai 2017 [16] | Japan | 27 | DFS,27 | Cholangiocarcinoma | NA | Frozen tissue | qRT-PCR | 82 | Median | 2.36 (1.18,4.17) | 2.47 (1.10,5.56) | ||
Zhou 2017 [47] | China | 51 | HCC | I–III | Frozen tissue | qRT-PCR | 42 | Normal | 1.23 (0.78,1.96) | ||||
Chen 2016 [11] | China | 86 | DFS,86 | Osteosarcoma | I–IV | Frozen tissue | qRT-PCR | 60 | Median | 2.14 (1.14,4.02) | 2.04 (1.22,3.40) | ||
Jiang 2016 [17] | China | 41 | Gastric cancer | I–III | Frozen tissue | qRT-PCR | 36 | Normal | 2.05 (1.03,4.08) | ||||
Yuan 2016 [14] | China | 56 | Lymphoma | NA | Frozen tissue | qRT-PCR | 50 | Median | 1.23 (0.94,1.61) | ||||
He 2014 [15] | China | 73 | DFS,73 | Cervical cancer | I–IV | Frozen tissue | qRT-PCR | 86 | Normal | 1.41 (0.30,6.63) | 1.73 (0.14,21.52) | ||
Li 2014 [21] | China | 102 | HCC | I–III | Frozen tissue | qRT-PCR | 72 | Normal | 0.45 (0.22,0.90) | ||||
Wang 2012 [48] | China | DFS,100 | NSCLC | I–III | Frozen tissue | qRT-PCR | 96 | Normal | 0.21 (0.09,0.50) | ||||
Hashimoto 2019 [49] | America (AA) | 36 | Prostate cancer | I–IV | Frozen tissue | qRT-PCR | 260 | Mean | 22.4 (2.27,221.3) | ||||
America (EA) | 57 | Prostate cancer | I–IV | Frozen tissue | qRT-PCR | 250 | Mean | 1.10 (0.21,5.74) | |||||
Ulivi 2019 [50] | Italy | 83 | DFS,85 | NSCLC | I–IIIA | Serum | qRT-PCR | 160 | Median | 1.35 (1.08,1.69) | 1.35 (1.08,1.69) | ||
Hu 2018 [51] | China | 110 | HCC | NA | Serum | qRT-PCR | 60 | Median | 6.58 (3.04,14.24) | ||||
Ecke 2017 [52] | Germany (TC) | 100 | Bladder-cancer | NA | Frozen tissue | qRT-PCR | 156 | Median | 0.99 (0.82,1.20) | ||||
Germany (VC) | 56 | Bladder-cancer | NA | Frozen tissue | qRT-PCR | 156 | Median | 1.02 (0.53,1.96) | |||||
Li 2017 [22] | China | 85 | Glioma | NA | Frozen tissue | qRT-PCR | 36 | Mean | 2.22(1.38,3.56) | ||||
Chang 2016 [23] | China (TC) | 85 | DFS,85 | HCC | I–III | Frozen tissue | qRT-PCR | 66 | Normal | 1.01 (0.38,2.72) | 2.02 (1.33,3.07) | ||
China (VC) | 65 | DFS,65 | HCC | I–III | Frozen tissue | qRT-PCR | 80 | Normal | 1.93 (1.30,2.87) | 1.73 (1.16,2.58) | |||
Sheng 2015 [24] | China | 86 | Glioma | NA | Frozen tissue | qRT-PCR | 36 | Median | 4.39 (1.50,12.82) | ||||
Wang 2014 [25] | China | 97 | DFS,97 | HCC | I–IV | Frozen tissue | qRT-PCR | 60 | Median | 2.52 (1.24,5.15) | 4.00 (1.52,10.54) | ||
Kjersem 2014 [30] | Norway | 150 | PFS,150 | Colorectal cancer | NA | Serum | qRT-PCR | NA | Median | 1.31 (0.96,1.79) | 1.40 (1.05,1.86) | ||
Colangelo 2013 [26] | Italy | 80 | Colorectal Cancer | I–IV | Frozen tissue | qRT-PCR | 108 | Mean | 5.99 (1.99,18.03) | ||||
Zhao 2013 [31] | China | 52 | Pancreatic cancer | I–IV | Frozen tissue | qRT-PCR | 36 | Median | 2.84 (1.25,6.45) | ||||
Nakatani 2012 [53] | Italy | 49 | Sarcoma | NA | Frozen tissue | qRT-PCR | 217 | Median | 2.11 (1.22,3.63) |
Baseline characteristics of eligible studies
Assessment of methodological quality
Study [Ref.] | Quality evaluation of prognosis study | Total scorea | Level of evidenceb | |||||
---|---|---|---|---|---|---|---|---|
Study participation | Study attrition | Prognostic factor measurement | Outcome measurement | Study confounding | Statistical analysis and reporting | |||
Jia 2019 [44] | Yes | Partly | Yes | Yes | Partly | Yes | 7 | 2b |
Peng 2018 [18] | Yes | Partly | Yes | Yes | Partly | Yes |
7
| 2b |
Liu 2018 [45] | Yes | Partly | Partly | Yes | Partly | Yes |
5
| 2b |
Yang 2018 [46] | Yes | Partly | Yes | Yes | Partly | Yes |
7
| 2b |
Asukai 2017 [16] | Partly | Partly | Partly | Yes | Partly | Partly |
6
| 2b |
Zhou 2017 [47] | Yes | Partly | Yes | Partly | Partly | Partly |
7
| 2b |
Chen 2016 [11] | Yes | Partly | Yes | Partly | Partly | Partly |
5
| 2b |
Jiang 2016 [17] | Partly | Partly | Partly | Yes | Partly | Partly | 5 | 2b |
Yuan 2016 [14] | Yes | Partly | Yes | Yes | Partly | Yes |
8
| 1b |
He 2014 [15] | Yes | Yes | Yes | Yes | Partly | Yes | 8 | 1b |
Li 2014 [21] | Yes | Yes | Yes | Yes | Partly | Yes | 7 | 2b |
Wang 2012 [48] | Partly | Partly | Yes | Yes | Partly | Yes | 6 | 2b |
Hashimoto 2019 [49] | Yes | Yes | Yes | Yes | Partly | Yes | 8 | 1b |
Ulivi 2019 [50] | Partly | Partly | Yes | Yes | Partly | Yes | 6 | 2b |
Hu 2018 [51] | Yes | Yes | Yes | Partly | Partly | Partly | 9 | 2b |
Ecke 2017 [52] | Yes | Partly | Yes | Yes | Partly | Yes | 7 | 2b |
Li 2017 [22] | Yes | Partly | Yes | Yes | Partly | Yes | 7 | 2b |
Chang 2016 [23] | Yes | Yes | Yes | Partly | Partly | Partly | 8 | 2b |
Sheng 2015 [24] | Partly | Partly | Yes | Yes | Partly | Yes | 7 | 2b |
Kjersem 2014 [30] | Partly | Partly | Yes | Partly | Partly | Partly | 6 | 2b |
Wang 2014 [25] | Partly | Partly | Yes | Yes | Partly | Yes | 7 | 2b |
Colangelo 2013 [26] | Partly | Partly | Yes | Partly | Partly | Partly | 5 | 2b |
Zhao 2013 [31] | Partly | Partly | Yes | Yes | Partly | Yes | 6 | 2b |
Nakatani 2012 [53] | Partly | Partly | Partly | Yes | Partly | Yes | 5 | 2b |
Quantitative synthesis
The expression of miRNA-130a and patients’ survival
Comparisons (miRNA-130 family) | Heterogeneity test | Summary HR (95% CI) | Hypothesis test | Studies | |||
---|---|---|---|---|---|---|---|
Q
|
P
| I2 (%) |
Z
|
P
| |||
miRNA-130a | |||||||
OS | |||||||
Total | 22.74 | 0.01 | 56 | 1.58 (1.21,2.06) | 3.34 | < 0.001 | 11 |
Tissue | 21.28 | 0.01 | 62 | 1.54 (1.11,2.14) | 2.60 | 0.009 | 9 |
Serum | 1.00 | 0.32 | 0 | 1.65 (1.14,2.38) | 2.65 | 0.008 | 2 |
Subgroup differences | 0.07 | 0.79 | 0 | ||||
Cancer subtypes | |||||||
Gastric cancer | 1.94 | 0.38 | 0 | 1.81 (1.34,2.45) | 3.83 | < 0.001 | 3 |
Other cancers | 18.30 | 0.01 | 62 | 1.46 (1.01,2.08) | 2.11 | 0.03 | 8 |
DFS | |||||||
Total | 24.08 | < 0.01 | 79 | 1.35 (0.72,2.52) | 0.93 | 0.35 | 6 |
Tissue | 23.91 | < 0.01 | 83 | 1.32 (0.52,3.40) | 0.58 | 0.56 | 5 |
Serum | – | – | – | 1.38 (0.99,1.91) | 0.21 | 0.83 | 1 |
Subgroup differences | 0.01 | 0.94 | 0 | ||||
miRNA-130b | |||||||
OS | |||||||
Total | 60.10 | < 0.01 | 77 | 1.95 (1.47,2.59) | 4.65 | < 0.001 | 15 |
Tissue | 44.46 | < 0.01 | 75 | 2.01 (1.39,2.91) | 3.71 | < 0.001 | 12 |
Serum | 15.50 | < 0.01 | 87 | 1.96 (1.09,3.54) | 2.23 | 0.03 | 3 |
Subgroup differences | 0.01 | 0.94 | 0 | ||||
Ethnicity | |||||||
Asian | 12.15 | 0.06 | 51 | 2.55 (1.77,3.69) | 5.00 | < 0.001 | 7 |
Caucasian | 23.95 | < 0.01 | 71 | 1.47 (1.08,1.99) | 2.45 | 0.01 | 8 |
Cancer subtypes | |||||||
HCC | 10.59 | 0.01 | 72 | 2.43 (1.28,4.63) | 8.24 | 0.004 | 4 |
Other cancers | 30.80 | < 0.01 | 74 | 1.75 (1.30,2.37) | 3.67 | < 0.001 | 11 |
DFS/PFS | |||||||
Total | 7.38 | 0.12 | 46 | 1.53 (1.31,1.77) | 5.53 | < 0.001 | 5 |
Tissue | 2.48 | 0.29 | 19 | 1.98 (1.50,2.62) | 4.85 | < 0.001 | 3 |
Serum | 0.03 | 0.86 | 0 | 1.37 (1.15,1.64) | 3.46 | < 0.001 | 2 |
Subgroup differences | 4.87 | 0.03 | 79.5 | ||||
Cancer subtypes | |||||||
HCC (DFS) | 2.48 | 0.29 | 19 | 1.98 (1.50,2.62) | 4.85 | < 0.001 | 3 |
Other cancers | 0.03 | 0.86 | 0 | 1.37 (1.15,1.64) | 3.46 | < 0.001 | 2 |
The expression of miRNA-130b and patients’ survival
Test of heterogeneity
Comparisons | Coef. | Std. Err. |
t
|
P
| 95% CI |
---|---|---|---|---|---|
miRNA-130a | |||||
Language | − 0.408 | 0.382 | − 1.07 | 0.327 | − 1.342 to 0.528 |
Publication year | − 1.272 | 0.734 | − 1.73 | 0.134 | − 3.069 to 0.525 |
Cancer type | 0.549 | 0.710 | 0.77 | 0.469 | − 1.188 to 2.287 |
Ethnica | – | – | – | – | – |
Assaya | – | – | – | – | – |
Sample size | − 0.279 | 0.372 | − 0.75 | 0.481 | − 0.630 to 1.189 |
Follow-up | − 0.308 | 0.378 | − 0.81 | 0.446 | − 1.235 to 0.617 |
Cut-off | − 0.506 | 0.385 | − 1.31 | 0.237 | − 1.447 to 0.436 |
miRNA-130b | |||||
Languagea | – | – | – | – | – |
Publication year | 0.306 | 0.458 | 0.67 | 0.523 | − 0.751 to 1.362 |
Cancer type | − 0.001 | 0. 542 | − 0.00 | 0.999 | − 1.250 to 1.248 |
Ethnic | − 0.678 | 0.606 | − 112 | 0.296 | − 2.076 to 0.720 |
Assaya | – | – | – | – | – |
Sample size | 0.107 | 0.568 | 0.19 | 0.856 | − 1.202 to 1.416 |
Follow-up | − 0.169 | 0.600 | − 0.28 | 0.786 | − 1.552 to 1.215 |
Cut-off | 0.178 | 0.318 | 0.56 | 0.591 | − 0.556 to 0.912 |